Wave Life Sciences Ltd (NASDAQ:WVE) insider Michael A. Panzara sold 3,058 shares of the business’s stock in a transaction that occurred on Friday, July 5th. The stock was sold at an average price of $26.94, for a total transaction of $82,382.52. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Shares of NASDAQ WVE opened at $26.04 on Friday. The firm has a market cap of $899.80 million, a P/E ratio of -5.15 and a beta of 0.83. Wave Life Sciences Ltd has a 52-week low of $22.25 and a 52-week high of $56.00. The company has a quick ratio of 2.39, a current ratio of 2.39 and a debt-to-equity ratio of 0.16. The stock has a 50 day moving average price of $25.40.

Wave Life Sciences (NASDAQ:WVE) last issued its quarterly earnings results on Friday, May 10th. The company reported ($1.36) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.19) by ($0.17). The firm had revenue of $3.03 million during the quarter, compared to analyst estimates of $9.66 million. Wave Life Sciences had a negative return on equity of 120.60% and a negative net margin of 971.48%. On average, sell-side analysts expect that Wave Life Sciences Ltd will post -4.23 earnings per share for the current year.

WVE has been the topic of a number of research reports. Mizuho set a $65.00 target price on shares of Wave Life Sciences and gave the stock a “buy” rating in a report on Saturday, June 29th. ValuEngine lowered shares of Wave Life Sciences from a “buy” rating to a “hold” rating in a report on Tuesday, April 16th. BidaskClub lowered shares of Zynga from a “buy” rating to a “hold” rating in a report on Tuesday, June 18th. SunTrust Banks boosted their target price on shares of Perrigo to $51.00 and gave the stock a “hold” rating in a report on Monday, May 20th. Finally, HC Wainwright lowered shares of Hydrogenics from a “buy” rating to a “neutral” rating in a report on Friday, June 28th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $50.80.

Several hedge funds and other institutional investors have recently modified their holdings of WVE. Citigroup Inc. lifted its position in shares of Wave Life Sciences by 189.4% in the 4th quarter. Citigroup Inc. now owns 2,807 shares of the company’s stock worth $118,000 after purchasing an additional 1,837 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its position in shares of Wave Life Sciences by 17.9% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 3,045 shares of the company’s stock worth $118,000 after purchasing an additional 462 shares during the period. Amundi Pioneer Asset Management Inc. lifted its position in shares of Wave Life Sciences by 45.0% in the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 2,900 shares of the company’s stock worth $122,000 after purchasing an additional 900 shares during the period. Legal & General Group Plc lifted its position in shares of Wave Life Sciences by 17.9% in the 4th quarter. Legal & General Group Plc now owns 3,094 shares of the company’s stock worth $130,000 after purchasing an additional 469 shares during the period. Finally, SG Americas Securities LLC acquired a new position in shares of Wave Life Sciences in the 1st quarter worth approximately $140,000. Hedge funds and other institutional investors own 85.62% of the company’s stock.

About Wave Life Sciences

Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Further Reading: Current Ratio

Insider Buying and Selling by Quarter for Wave Life Sciences (NASDAQ:WVE)

Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.